Oliver J Ott1, Carolin Jeremias2, Udo S Gaipl2, Benjamin Frey2, Manfred Schmidt2, Rainer Fietkau2. 1. Department of Radiation Oncology, University Hospital Erlangen, Universitätsstraße 27, 91054, Erlangen, Germany. oliver.ott@uk-erlangen.de. 2. Department of Radiation Oncology, University Hospital Erlangen, Universitätsstraße 27, 91054, Erlangen, Germany.
Abstract
BACKGROUND: The aim of this study was to evaluate the long-term efficacy of two dose-fractionation schedules for radiotherapy of achillodynia. PATIENTS AND METHODS: Between February 2006 and February 2010, 112 evaluable patients were recruited for this prospective trial. All patients received orthovoltage radiotherapy. One course consisted of 6 fractions/3 weeks. In the case of insufficient remission of pain after 6 weeks, a second series was performed. Patients were randomly assigned to receive either single doses of 0.5 or 1.0 Gy. The endpoint was pain reduction. Pain was measured before, right after (early response), 6 weeks after (delayed response), and approximately 2 years after radiotherapy (long-term response) with a questionnaire-based visual analogue scale (VAS) and a comprehensive pain score (CPS). RESULTS: The median follow-up was 24 months (range, 11-56). The overall early, delayed, and long-term response rates for all patients were 84 %, 88 %, and 95 %, respectively. The mean VAS values before treatment for early, delayed, and long-term responses for the 0.5-Gy and 1.0-Gy groups were 55.7 ± 21.0 and 58.2 ± 23.5 (p = 0.53), 38.0 ± 23.2 and 30.4 ± 22.6 (p = 0.08), 35.5 ± 25.9 and 30.9 ± 25.4 (p = 0.52), and 11.2 ± 16.4 and 15.3 ± 18.9 (p = 0.16), respectively. The mean CPS values before treatment for early, delayed, and long-term responses were 8.2 ± 3.0 and 8.9 ± 3.3 (p = 0.24), 5.6 ± 3.1 and 5.4 ± 3.3 (p = 0.76), 4.4 ± 2.6 and 5.3 ± 3.8 (p = 0.58), and 2.2 ± 2.9 and 2.8 ± 3.3 (p = 0.51), respectively. No significant differences in long-term response quality between the two arms was found (p = 0.73). CONCLUSION:Radiotherapy is a very effective treatment for the management of benign achillodynia. For radiation protection, the dose for a radiotherapy series should not exceed 3.0 Gy.
RCT Entities:
BACKGROUND: The aim of this study was to evaluate the long-term efficacy of two dose-fractionation schedules for radiotherapy of achillodynia. PATIENTS AND METHODS: Between February 2006 and February 2010, 112 evaluable patients were recruited for this prospective trial. All patients received orthovoltage radiotherapy. One course consisted of 6 fractions/3 weeks. In the case of insufficient remission of pain after 6 weeks, a second series was performed. Patients were randomly assigned to receive either single doses of 0.5 or 1.0 Gy. The endpoint was pain reduction. Pain was measured before, right after (early response), 6 weeks after (delayed response), and approximately 2 years after radiotherapy (long-term response) with a questionnaire-based visual analogue scale (VAS) and a comprehensive pain score (CPS). RESULTS: The median follow-up was 24 months (range, 11-56). The overall early, delayed, and long-term response rates for all patients were 84 %, 88 %, and 95 %, respectively. The mean VAS values before treatment for early, delayed, and long-term responses for the 0.5-Gy and 1.0-Gy groups were 55.7 ± 21.0 and 58.2 ± 23.5 (p = 0.53), 38.0 ± 23.2 and 30.4 ± 22.6 (p = 0.08), 35.5 ± 25.9 and 30.9 ± 25.4 (p = 0.52), and 11.2 ± 16.4 and 15.3 ± 18.9 (p = 0.16), respectively. The mean CPS values before treatment for early, delayed, and long-term responses were 8.2 ± 3.0 and 8.9 ± 3.3 (p = 0.24), 5.6 ± 3.1 and 5.4 ± 3.3 (p = 0.76), 4.4 ± 2.6 and 5.3 ± 3.8 (p = 0.58), and 2.2 ± 2.9 and 2.8 ± 3.3 (p = 0.51), respectively. No significant differences in long-term response quality between the two arms was found (p = 0.73). CONCLUSION: Radiotherapy is a very effective treatment for the management of benign achillodynia. For radiation protection, the dose for a radiotherapy series should not exceed 3.0 Gy.
Authors: F Rödel; B Frey; U Gaipl; L Keilholz; C Fournier; K Manda; H Schöllnberger; G Hildebrandt; C Rödel Journal: Curr Med Chem Date: 2012 Impact factor: 4.530
Authors: Ralph Muecke; Oliver Micke; Berthold Reichl; Rainer Heyder; Franz-Josef Prott; M Heinrich Seegenschmiedt; Michael Glatzel; Oliver Schneider; Ulrich Schäfer; Guenther Kundt Journal: Acta Oncol Date: 2007 Impact factor: 4.089
Authors: Marcus Niewald; M Heinrich Seegenschmiedt; Oliver Micke; Stefan Graeber; Ralf Muecke; Vera Schaefer; Christine Scheid; Jochen Fleckenstein; Norbert Licht; Christian Ruebe Journal: Int J Radiat Oncol Biol Phys Date: 2012-07-25 Impact factor: 7.038
Authors: Matthias G Hautmann; Philipp Rechner; Matthias Hipp; Ulrich Neumaier; Felix Steger; Fabian Pohl; Markus Weber; Oliver Kölbl; Christoph Süß Journal: Strahlenther Onkol Date: 2019-07-25 Impact factor: 3.621
Authors: Michael Rückert; Lisa Deloch; Rainer Fietkau; Benjamin Frey; Markus Hecht; Udo S Gaipl Journal: Strahlenther Onkol Date: 2018-03-02 Impact factor: 3.621
Authors: Alexander Kaltenborn; Ulrich Martin Carl; Tanja Hinsche; Mirko Nitsche; Robert Michael Hermann Journal: Strahlenther Onkol Date: 2016-11-11 Impact factor: 3.621
Authors: Oliver Micke; Eyup Ugrak; Stefan Bartmann; Irenaeus A Adamietz; Ulrich Schaefer; Rebecca Bueker; Klaus Kisters; M Heinrich Seegenschmiedt; Khashayar Fakhrian; Ralph Muecke Journal: Radiat Oncol Date: 2018-04-19 Impact factor: 3.481